Thursday, November 19, 2026
Thalif Deen
- UN Secretary-General Kofi Annan Thursday met with top executives of six leading pharmaceutical firms and urged them to provide affordable medicines to the world’s poorest nations.
“I am pleased to tell you that the companies have agreed to continue and accelerate reducing prices substantially,” he said.
Annan said the proposed price cuts – which are yet to be determined – will specifically apply to the 48 least developed countries (LDCs), described as the poorest of the world’s poor.
Of the 48, he said, special emphasis will be placed on the medical needs of 33 LDCs from Africa. These include countries such as Burkina Faso, Burundi, Ethiopia, Gambia, Guinea-Bissau, Malawi, Rwanda, Sierra Leone, Sudan, Uganda and Zambia.
Annan met the six senior executives at a pre-arranged meeting in Amsterdam Thursday en route to New York following a visit to Geneva.
The six multinational pharmaceutical firms taking part in the meeting were: Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Glaxo Smith Kline, Hoffman-La Roche, and Pfizer.
Also attending the meeting were Gro Harlem Brundtland, director- general of the World Health Organisation (WHO), and Peter Piot, executive director of the Joint UN Programme on HIV/AIDS (UNAIDS).
Besides the offer of help to LDCs, Annan said he had also received a pledge that the six companies will continue to offer affordable medicines to other developing countries as well on a country by country basis.
The pharmaceutical companies also recognised the need to consider increased access to HIV/AIDS medicine to qualified non-governmental organisations (NGOs), and appropriate private companies offering health care to employees and local communities in these nations.
“Today’s commitments consolidate, and go beyond, the progress which individual companies had made in reducing prices since last May, when five of them signed a Joint Statement of Intent with the United Nations,” Annan noted.
“This represents a contribution to the global response to the epidemic, going much further than any of us could have predicted 12 months ago,” he added. “Encouraging the active participation of all partners in the fight against AIDS has become my personal priority,” Annan said.
The meeting comes at a time when multinational pharmaceutical firms have come under heavy fire for keeping the price of drugs, particularly those against AIDS, beyond the reach of patients in poorer nations.
And as a result, countries such as Brazil, South Africa and India have been producing cheaper generic drugs forcing some of the multinationals out of Third World markets.
Last month, an Indian company agreed to supply anti-AIDS drugs to an international relief agency, Doctors Without Borders, at 3.5 percent of the cost charged by Western pharmaceutical companies. The company agreed to sell the discounted drugs only if the relief agency distributed them free.
The Bombay-based Cipla Ltd agreed to sell an anti-retroviral cocktail for 350 dollars a year per patient compared with the 10,000 to 15,000 dollars per patient charged in the United States and Western Europe.
Jeffrey Sachs, Director of the Centre for International Development at Harvard University, says that there is perhaps no starker divide between rich and poor than that of public health.
“The rich are living longer and more healthily than ever, while the poor are increasingly falling victim to AIDS, malaria, tuberculosis and other emerging and re-emerging diseases,” he points.
Money, political will, wise stewardship by the pharmaceutical companies and good science from the world’s experts will all be needed to fight diseases, he argues.
Sachs also says that pharmaceutical companies should make their miracle drugs for AIDS and other killer diseases available at production cost to the poorer countries.
According to UN figures, some 36 million people are living with HIV or AIDS worldwide, with 5.3 million newly infected during 2000 alone. That same year, three million people died of AIDS, bringing the total number of deaths to 21.8 million, since the start of the epidemic.
The poorer African nations cannot simply afford the drugs because most of them have annual incomes of less than 200 dollars per person.
Africa, says Sachs, would probably need between 10 billion and 20 billion dollars a year from international donors for disease control, but it receives less than one billion dollars now.
Astrid Heiberg, President of the International Federation of Red Cross and Red Crescent Societies says that humanitarian needs should prevail over commercial concerns so that people have access to life-saving drugs in developing countries.
“The present balance of resource allocation and pricing of drugs is unacceptable and needs to be re-designed as it does not allow access to care and treatment for the vast majority of people living with HIV/AIDS”.
“This concern is relevant not only for HIV/AIDS patients but also for other major public health problems in developing countries,” Heiberg added.